169 related articles for article (PubMed ID: 36521928)
1. Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors.
Pani F; Yasuda Y; Rousseau ST; Bermea KC; Roshanmehr S; Wang R; Yegnasubramanian S; Caturegli P; Adamo L
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521928
[TBL] [Abstract][Full Text] [Related]
2. Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy.
Xie W; Zeng Y; Hu L; Hao J; Chen Y; Yun X; Lin Q; Li H
Front Immunol; 2022; 13():991656. PubMed ID: 36211409
[TBL] [Abstract][Full Text] [Related]
3. Distinct Cytokine Signatures in Thyroiditis Induced by PD-1 or CTLA-4 Blockade: Insights from a New Mouse Model.
Ippolito S; Di Dalmazi G; Pani F; Sabini E; Caturegli P
Thyroid; 2021 Dec; 31(12):1839-1849. PubMed ID: 34598661
[No Abstract] [Full Text] [Related]
4. Pre-existing Thyroiditis Ameliorates Papillary Thyroid Cancer: Insights From a New Mouse Model.
Pani F; Yasuda Y; Di Dalmazi G; Chalan P; Gabrielson K; Adamo L; Sabini E; Mariotti S; Caturegli P
Endocrinology; 2021 Oct; 162(10):. PubMed ID: 34331442
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations.
Kotwal A; Gustafson MP; Bornschlegl S; Kottschade L; Delivanis DA; Dietz AB; Gandhi M; Ryder M
Thyroid; 2020 Oct; 30(10):1440-1450. PubMed ID: 32323619
[No Abstract] [Full Text] [Related]
6. Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition.
Zhi J; Zhang P; Zhang W; Ruan X; Tian M; Guo S; Zhang W; Zheng X; Zhao L; Gao M
J Clin Endocrinol Metab; 2021 Jan; 106(1):91-107. PubMed ID: 32936899
[TBL] [Abstract][Full Text] [Related]
7. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
[TBL] [Abstract][Full Text] [Related]
8. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
[TBL] [Abstract][Full Text] [Related]
9. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.
Hayase E; Jenq RR
Genome Med; 2021 Jun; 13(1):107. PubMed ID: 34162429
[TBL] [Abstract][Full Text] [Related]
10. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
[TBL] [Abstract][Full Text] [Related]
11. IL-10 Restores MHC Class I Expression and Interferes With Immunity in Papillary Thyroid Cancer With Hashimoto Thyroiditis.
Lu ZW; Hu JQ; Liu WL; Wen D; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32348468
[TBL] [Abstract][Full Text] [Related]
12. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
[TBL] [Abstract][Full Text] [Related]
13. IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis.
Han LT; Hu JQ; Ma B; Wen D; Zhang TT; Lu ZW; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
Diagn Pathol; 2019 Jun; 14(1):52. PubMed ID: 31159823
[TBL] [Abstract][Full Text] [Related]
14. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
18. LAG3 blockade coordinates with microwave ablation to promote CD8
Shao D; Chen Y; Huang H; Liu Y; Chen J; Zhu D; Zheng X; Chen L; Jiang J
J Transl Med; 2022 Sep; 20(1):433. PubMed ID: 36180876
[TBL] [Abstract][Full Text] [Related]
19. Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors.
Krone P; Wolff A; Teichmann J; Maennicke J; Henne J; Engster L; Salewski I; Bergmann W; Junghanss C; Maletzki C
Oncoimmunology; 2023; 12(1):2230669. PubMed ID: 37396958
[TBL] [Abstract][Full Text] [Related]
20. Is diffuse and peritumoral lymphocyte infiltration in papillary thyroid cancer a marker of good prognosis?
Villagelin DG; Santos RB; Romaldini JH
J Endocrinol Invest; 2011 Dec; 34(11):e403-8. PubMed ID: 21765238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
